Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-29T07:19:47.786Z Has data issue: false hasContentIssue false

Nouveaux phosphorothioates dérivésde la naphthylméthylimidazoline et de la naphthyléthylimidazoline : applicationen radioprotection chimique

Published online by Cambridge University Press:  16 March 2005

B. Célariès
Affiliation:
Laboratoire d’hétérochimie fondamentale et appliquée, université Paul Sabatier, 118 route de Narbonne, 31062 Toulouse Cedex 4, France
C. Amourette
Affiliation:
Centre de recherches du Service de santé des Armées, 24 avenue des Maquis du Grésivaudan, 38702 La Tronche Cedex, France
C. Lion
Affiliation:
ITODYS, Université Paris-VII, 1 rue Guy de la Brosse, 75005 Paris, France
G. Rima
Affiliation:
Laboratoire d’hétérochimie fondamentale et appliquée, université Paul Sabatier, 118 route de Narbonne, 31062 Toulouse Cedex 4, France
Get access

Abstract

Dans ce travail, nous avons synthétisé des phosphorothioates dérivés de la 2‑(1‑naphthylméthyl)-2-imidazoline et de la 2-[1-(1-naphthyl)éthyl]-2-imidazoline afin d’évaluer, in vivo chez la souris, leur degré de protection contre les effets des rayonnements γ. Tous ces composés ont montré une activité radioprotectrice remarquable (facteur de réduction de dose compris entre 1,5 et 1,9) ce qui les classent parmi les plus actifs actuellement connus dans le domaine de la radioprotection chimique. Ces composés peuvent également présenter un intérêt dans le domaine des traitements de chimio- et de radio-thérapie.

Type
Research Article
Copyright
© EDP Sciences, 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bonet-Maury, P., Patti, F. (1950) L’irradiation mortelle de la souris par les rayons X et γ. Essais thérapeutiques, J. Radiol. Electrol. Arch. Electr. Méd. 31, 286-290.
Célariès, B., Court, L., Lion, C., Rima, G., Roman, V. (2001a) Organometallic compounds of silicon and germanium in chemical radioprotection, Main Group Met. Chem. 25, 58.
Célariès, B., Rima, G., Court, L., Lion, C., Roman, V., Laval, J.D. (2001b) Radioprotective activity and synthesis of siladithioacetals and germadithioacetals derived from N-substituted naphthylethylimidazoline, Metal-Based Drugs 8, 199-210. CrossRef
Célariès, B., Amourette, C., Lion, C., Rima, G. (2003a) Radioprotective activity of metalladithioacetals derived from N-substituted naphthylethylimidazoline, Appl. Organomet. Chem. 17, 135-138. CrossRef
Célariès, B., Amourette, C., Lion, C., Rima, G. (2003b) Synthesis and radioprotective study of new siladithioacetals and germadithioacetals, Appl. Organomet. Chem. 17, 561-569. CrossRef
Davidson D.E., Grenan M.M., Sweeney T.R. (1980) Radiation Sensitizers. Their use in the clinical management of cancer (Luther W. Brady, Ed.) p. 309. Masson pub., USA.
Fatôme, M., Sentenac-Roumanou, H., Lion, C., Satgé, J., Fourtinon, M., Rima, G. (1984) Radioprotective effect of germanium dithioacetals of cysteamine and methylcysteamine, Eur. J. Med. Chem. 19, 119-122.
Fatôme, M., Sentenac-Roumanou, H., Lion, C., Satgé, J., Rima, G. (1988) Study of germathiazolidines and germylated dithioacetals derived from N-substituted cysteamine and methylcysteamine: synthesis and radioprotective activity, Eur. J. Med. Chem. 23, 257-266. CrossRef
Finney D.J. (1971) Probit. Analysis: a statistical treatment of the sigmoid response curve, 3rd edn. Cambridge University Press.
Laval, J.D., Roman, V., Laduranty, J., Miginiac, L., Lion, C., Sentenac-Roumanou, H., Fatôme, M. (1993) Radioprotective effect of low doses of 2-(1-naphthylmethyl)-2-imidazoline alone or associated with phosphorothioates, Eur. J. Med. Chem. 28, 709-713. CrossRef
Piper, J.R., Stringfellow, C.R., Elliot, R.D., Johnston, T.P. (1969a) S-2-(omega-aminoalkylamino)ethyl dihydrogen phosphorothioates and related compounds as potential antiradiation agents, J. Med. Chem. 12, 236-243. CrossRef
Piper, J.R., Stringfellow, C.R., Johnston, T.P. (1969b) Terminally substituted S-2-(omega-aminoalkylamino)ethyl dihydrogen phosphorothioates and related compounds as potential antiradiation agents, J. Med. Chem. 12, 244-253. CrossRef
Porta, C., Maiolo, A., Tua, A., Grignani, G. (2000) Amifostine, a reactive oxygen species scavenger with radiation- and chemo-protective properties, inhibits in vitro platelet activation induced by ADP, collagen or PAF, Haematologica. 85, 820-825.
Rima, G., Satgé, J., Fatôme, M., Laval, J.D., Sentenac-Roumanou, H., Lion, C., Lazraq, M. (1991) Syntheses and radioprotective activities of trithiagermatranes, trithiasilatranes, germylated oxide and sulfide with cysteamine and N-(2-thioethyl)-1,3-diaminopropane hydrochloride ligands, Eur. J. Med. Chem. 26, 291-297. CrossRef
Rima, G., Satgé, J., Sentenac-Roumanou, H., Fatôme, M., Lion, C., Laval, J.D. (1993) New organogermylated compounds N-substituted by naphthylmethylimidazoline hydrochloride, and imidazoline: synthesis and radioprotective activity, Eur. J. Med. Chem. 28, 761-767. CrossRef
Rima, G., Satgé, J., Sentenac-Roumanou, H., Fatôme, M., Laval, J.D., Lion, C., Alazard, O., Chabertier, P. (1994) Synthesis and radiopharmacological study of new metalated thiazolidines and dithioacetals of N-allyl-substituted cysteamine and methylcysteamine, Appl. Organomet. Chem. 8, 481-490. CrossRef
Rima, G., Satgé, J., Sentenac-Roumanou, H., Fatôme, M., Laval, J.D., Lion, C., Dagiral, R. (1996) New germaheterocycles, germadithioacetals and a germylated oxide and sulfide derived from cysteamine, methylcysteamine and N-substituted cysteamine: synthesis and radioprotective activity, Appl. Organomet. Chem. 10, 113-123. 3.0.CO;2-V>CrossRef
Rima, G., Satgé, J., Sentenac-Roumanou, H., Fatôme, M., Laval, J.D., Lion, C., Thiriot, C., Dagiral, R., Martin, C. (1997) Synthesis and radioprotective properties of new metallathiazolidines, dialkyloxathiagermolanes, dialkylgermocanes and metalladithioacetals, Main Group Met. Chem. 20, 255-267. CrossRef
Rima, G., Satgé, J., Dagiral, R., Lion, C., Fatôme, M., Roman, V., Laval, J.D. (1998) Synthesis and radioprotective activity of new organosilicon and germanium compounds, Metal-Based Drugs 5, 139-146. CrossRef
Rima, G., Satgé, J., Dagiral, R., Lion, C., Fatôme, M., Roman, V., Laval, J.D. (1999a) Synthesis and application of new organometallic compounds of silicon and germanium in chemical radioprotection, Appl. Organomet. Chem. 13, 583-594. 3.0.CO;2-D>CrossRef
Rima, G., Satgé, J., Dagiral, R., Lion, C., Sentenac-Roumanou, H., Fatôme, M., Roman, V., Laval, J.D. (1999b) A review on the radioprotective activity of organogermanium and organosilicon compounds, Metal-Based Drugs 6, 49-60. CrossRef
Satgé, J., Cazes, A., Bouchaut, M., Fatôme, M., Sentenac-Roumanou, H., Lion, C. (1982) Synthesis and radioprotective activity of germa- and silathiazolidines, Eur. J. Med.Chem. 17, 433-436.
Satgé, J., Rima, G., Fatôme, M., Sentenac-Roumanou, H., Lion, C. (1989) Syntheses and radioprotective activities of germatranes, silatranes, germylated oxides and sulfides with cysteamine, methylcysteamine and N-(2-thioethyl)-1,3-diaminopropane hydrochloride ligands, Eur. J. Med. Chem. 24, 48-54. CrossRef
Washburn, L.C., Carlton, J.E., Hayes, R.L., Yuhas, J.M. (1974) Distribution of WR 2721 in normal and malignant tissues of mice and rats bearing solid tumors. Dependence on tumor type, drug dose, and species, Radiat. Res. 59, 475-483. CrossRef
Washburn, L.C., Rafter, J.J., Hayes, R.L., Yuhas, J.M. (1976) Prediction of the effective radioprotective dose of WR-2721 in humans through an interspecies tissue distribution study, Radiat. Res. 66, 100-105. CrossRef
Yuhas, J.M. (1970) Biological factors affecting the radioprotective efficiency of S-2-[2-aminopropylamino] ethylphosphorothioic acid (WR-2721). LD50/30j doses, Radiat. Res. 44, 621-628. CrossRef
Yuhas, J.M. (1972) Improvement of lung tumor radiotherapy through differential chemoprotection of normal and tumor tissue, J. Natl-Cancer Inst. 48, 1255-1257.
Yuhas, J.M. (1973) Radiotherapy of experimental lung tumors in the presence and absence of a radioprotective drug, S-2-(3-aminopropylamino)ethylphosphorothioic acid (WR-2721), J. Natl-Cancer Inst. 50, 69-78. CrossRef